Targeting MCT4 for treatment of advanced prostate cancers : inhibiting cell proliferation and enhancing anticancer immunity through suppressing lactic acid secretion and elevated glycolysis
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in North American males and a leading cause of cancer deaths. The lack of effective treatment options for advanced PCa such as AR-positive castration-resistant PCa (CRPC-AD) and the highly aggressive AR-negative CRPC, e.g. neu...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2017
|
| Online Access: | http://hdl.handle.net/2429/63874 |